Podcast CME Course Information

Exam: Exam 434: Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease

Issue: July 9, 2019

Learning Objectives

Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease

Upon completion of this podcast, listeners will be able to counsel their patients that current epidemiologic data do not support a causal link between β2AR agonists and antagonists and PD risk. They can explain that: 1. The association of β2AR agonists to be indirectly mediated by smoking, which is repeatedly associated with reduced risk of PD. 2. The association of β2AR antagonists indicates reverse causation, with PD symptoms triggering their prescription rather than β2AR antagonists causing PD.

Recommended Audience

This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.

Core Competencies

  • Patient Care
  • Medical Knowledge


Program Accreditations Subcommittee (PAS) is responsible for reviewing and evaluating all CME programs. Joseph F. Kass, MD, JD, FAAN, has received personal compensation for activities as an expert witness in litigation and in an editorial capacity for the American Academy of Neurology. Barney J. Stern, MD, FAAN, has received personal compensation for book chapter contributions. The other members of the committee (Samir Belagaje, MD; J. Clay Goodman, MD, FAAN; Omotola A. Hope, MD; Shannon M. Kilgore, MD, FAAN) and AAN staff (Kristine Mitchell) report no disclosures. Robert A. Gross, MD, PhD, FAAN, has received funding for travel and/or speaker honoraria from the American Academy of Neurology; receives a stipend as Editor-in-Chief of Neurology; has received consultant fees from GlaxoSmithKline and Harris Interactive; has served on speakers' bureaus for Abbott, UCB, and GlaxoSmithKline; has conducted clinical trials over the past 5 years funded by GlaxoSmithKline, UCB, Ortho-McNeil, Pfizer, and Marinus, but has ceased participation in industry-sponsored clinical trials and speakers' bureaus since his appointment as Neurology EIC in 2010; and has received research support from the Department of the Army, UCBPharma, and University of Rochester Medical Center/NIH. Dr. Stacey Clardy serves as Podcast Editor for Neurology® and has received research support forWestern Institute for Biomedical Research (WIBR). Dr. Jeff Ratliff serves as Podcast Deputy Editor for Neurology andreceived a speaker honorarium from Haverford College. AAN staff members editing the test (P Baskin, L Kleffman, K Aman Ramm) have no disclosures. The CME Journal Editors who have reviewed the exam are James WM Owens Jr., MD PhD, who receives royalties from UpToDate, Waltham, MA; grant support from NIH (PI, K08NS054882); and a stipend in his editorial capacity for Neurology and Adam Kelly, MD, who has served as Guest Editor of Continuum (April 2014) and receives a stipend in his editorial capacity for Neurology.

Dr. Franziska Hopfner has received commercial research support from B. Braun-Stiftung; has received governmental research funding from the University of Kiel; and has received foundation/society research funding from Stiftung Felgenhauer zur Förderung junger Neurowissenschaftler. Dr. Jeffrey Ratliff has received speaker or travel honoraria from Teva and US WorldMeds LLC; serves as the Deputy Section Editor for Neurology Podcast; has served as a consultant for UCB Pharmaceuticals, US World Meds, LLC, Medscape, and Retrophin, Inc.; and has served on speaker’s bureaus for Teva and US WorldMeds LLC. Dr. Jason Crowell serves as an editor for the Neurology Podcast. Dr. Jerzy Szaflarski has served on the scientific advisory board for UCB Pharmaceuticals, Inc., SK Life Sciences, Inc., and GW Pharmaceuticals, Inc; has received funding for travel or speaker honoraria from SK Life Sciences, Inc., UCB Pharmaceuticals, Inc., and GW Pharmaceuticals, Inc.; has served on the editorial boards of Epilepsy Currents, Journal of Epileptology, Folia Medica Copernicana, Journal of Medical Science, Restorative Neurology and Neuroscience, Conference Papers in Medicine, and Epilepsy and Behavior; has received commercial research support from SAGE Pharmaceuticals Inc., GW Pharmaceuticals Inc., NeuroPace Inc., and UCB Pharmaceuticals Inc,; has received governmental research support from the NIH and the University of Cincinnati; has received foundation/society research support from Charles Shor Foundation for Epilepsy Research; and has acted as a medico-legal expert in legal proceedings.

The other participants report no disclosures.

CME Expiration

CME expires three years after publication date or sooner if podcasts are deemed out of date by reviewers.


The American Academy of Neurology Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Credit™

The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The American Academy of Neurology holds copyright for all materials in this exam.


Any information regarding the identity of individuals taking the exam or their exam scores will be kept confidential.

Hardware and Software Requirements

A computer with a web browser such as Internet Explorer, Firefox, Safari, or Google Chrome is required.

Start this exam

For More Information

Patty Baskin

Executive Editor, Neurology®
(612) 928-6021